Receive The Newest Study Notifications

Multi-center platform trial sponsored by the Healey Center will simultaneously assess multiple drug regimens Zilucoplan selected by leading experts in ALS as one of the first therapeutic candidates to be tested BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra...

DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment for the trial consists of 12 severe patients (MELD 21-30) and 7...

TrialSpark, a technology company committed to improving the speed, access, and reliability of clinical trials, and Pfizer have entered into a multi-year collaboration to extend Pfizer clinical trials to community doctors who have not previously been study...

Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor...

Study will yield reliable benchmarks on trial cost and efficiency, enabling participants to realize dramatic cost savings The WIRB-Copernicus Group®'s (WCG™) Clinical Services Division is pleased to announce that enrollment in WCG KMR Group's 2019 Clinical Trial Cost...

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the NSABP Foundation, Inc. (NSABP) has enrolled the first patient in the study: A Phase II Clinical Trial of Pembrolizumab in Combination...

When patients are searching for more information on ailments or medical conditions, their first stop will most likely be Google. That said, companies specializing in clinical trial patient recruitment must be cognizant of those searching habits and take advantage of...

KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 San Diego, CA (GLOBE NEWSWIRE) - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical...

Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients. DURHAM, N.C., Sept. 17, 2019 /PRNewswire-PRWeb/ -- Results of a...

- CNTX-4975 Phase 3 clinical development program fully enrolled - - VICTORY-1 pivotal and VICTORY-3 open-label topline results expected in Q1 2020; VICTORY-2 pivotal results expected in Q3 2020 - BOSTON, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics...

GRONINGEN, The Netherlands, September 17, 2019 / B3C newswire / -- Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, has today announced positive data from its ENCASE I* clinical trial. The ENCASE I...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata. Topline data from...

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular...

Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Phase IIb HbA1c trial evaluating Oramed's...

Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has...

Combination Inhibits Upstream and Downstream Targets in Oncogenic RAS Signaling Pathway, Offering Potential for Synergistic Anti-Tumor Benefit REVOLUTION Medicines, Inc., a clinical-stage oncology company focused on developing novel targeted therapies to inhibit...

CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Hannover Medical...

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has...

International Phase 1 clinical trials expected to start in 2019 In France, the studies will be conducted at Institut Curie and Toulouse-Oncopole Clinical trials co-funded by Transgene and its collaboration partner NEC Transgene (TNG.PA) (Euronext Paris: TNG), a...

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that the first 30 subjects have been...